Current Report Filing (8-k)
November 21 2016 - 8:48AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
:
November 19
, 2016
Kadmon Holdings
, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
Delaware
|
|
001-
37841
|
|
27
-
3576929
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
450 East 29
th
Street
New York, NY
|
|
10016
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code (
212
) 3
08
-
6000
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On
November 19
, 2016, Kadmon Holdings, Inc. (the “Company”) issued a press release announcing
additional data from its ongoing Phase 2a clinical study demonstrating the safety of tesevatinib, the Company’s oral tyrosine kinase inhibitor, for the treatment of autosomal dominant polycystic kidney disease. The data will be presented in a poster session on Saturday, November 19
, 2016
at the American Society of Nephrology Kidney Week 2016 in Chicago, IL
. The full text of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
|
|
ITEM 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release, dated
November 19
, 2016
, issued by Kadmon Holdings, Inc.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Kadmon Holdings, Inc.
|
|
|
|
Date:
November 21
, 2016
|
|
|
|
/s/ Konstantin Poukalov
|
|
|
|
|
Konstantin Poukalov
|
|
|
|
|
Executive Vice President, Chief Financial Officer
|
Kadmon (NYSE:KDMN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kadmon (NYSE:KDMN)
Historical Stock Chart
From Sep 2023 to Sep 2024